Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	Apr. 27, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	0000899923
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		68,118,450

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2017	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 123.8	$ 68.5
Marketable investment securities	48.3	90.5
Prepaid expenses	9.5	18.4
Inventory	47.4	38.3
Trade accounts receivable, less allowance for doubtful accounts of $8.1 March 31, 2017 and $6.8 June 30, 2016	114.8	91.7
Prepaid taxes	0.1	3.8
Other receivables	4.4	3.3
Total current assets	348.3	314.5
Property, plant and equipment, net	53.0	58.3
Long-term marketable investment securities	53.4	79.9
Intangibles, net	498.1	227.5
Goodwill	315.0	195.3
Other assets		5.0
Total assets	1,267.8	880.5
Current liabilities:
Accounts payable	26.8	21.1
Accrued liabilities	64.0	49.5
Short-term contingent consideration	128.2
Deferred revenue	2.7	1.7
Total current liabilities	221.7	72.3
Unrecognized tax benefits	24.9	24.0
Other long-term liabilities	7.2	7.8
Contingent consideration	14.3	10.4
Long-term debt	167.1
Long-term deferred taxes	84.7	17.9
Total liabilities	519.9	132.4
Commitments and contingencies
Stockholders’ equity:
Common stock, 68.1 and 69.1 shares outstanding at March 31, 2017 and June 30, 2016 respectively	0.7	0.7
Additional paid-in capital	839.5	830.1
Accumulated other comprehensive loss	(10.6)	(9.5)
Accumulated deficit	(81.4)	(73.2)
Total Myriad Genetics, Inc. stockholders’ equity	748.2	748.1
Non-Controlling Interest	(0.3)
Total stockholders' equity	747.9	748.1
Total liabilities and stockholders’ equity	$ 1,267.8	$ 880.5

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Mar. 31, 2017	Jun. 30, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 8.1	$ 6.8
Common stock, shares outstanding	68.1	69.1

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Molecular diagnostic testing	$ 185.2	$ 177.4	$ 534.2	$ 532.0
Pharmaceutical and clinical services	11.7	13.1	36.7	35.4
Total revenue	196.9	190.5	570.9	567.4
Costs and expenses:
Cost of molecular diagnostic testing	37.9	33.6	109.5	98.6
Cost of pharmaceutical and clinical services	6.4	6.6	19.1	18.7
Research and development expense	17.6	17.2	55.6	51.1
Selling, general, and administrative expense	122.1	90.5	354.3	267.8
Total costs and expenses	184.0	147.9	538.5	436.2
Operating income	12.9	42.6	32.4	131.2
Other income (expense):
Interest income	0.3	0.3	0.9	0.5
Interest expense	(1.5)		(4.8)	(0.2)
Change in the fair value of contingent consideration	(5.2)		(2.0)
Other	1.5	0.2	(2.4)	0.2
Total other income (expense):	(4.9)	0.5	(8.3)	0.5
Income before income tax	8.0	43.1	24.1	131.7
Income tax provision	3.8	8.6	15.2	29.7
Net income	4.2	34.5	8.9	102.0
Net loss attributable to non-controlling interest	0.0	0.0	(0.1)	0.0
Net income attributable to Myriad Genetics, Inc. stockholders	$ 4.2	$ 34.5	$ 9.0	$ 102.0
Earnings per share:
Basic	$ 0.06	$ 0.49	$ 0.13	$ 1.46
Diluted	$ 0.06	$ 0.47	$ 0.13	$ 1.39
Weighted average shares outstanding:
Basic	68.1	70.9	68.1	70.1
Diluted	68.3	73.5	68.5	73.2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income attributable to Myriad Genetics, Inc. shareholders	$ 4.2	$ 34.5	$ 9.0	$ 102.0
Unrealized gain (loss) on available-for-sale securities, net of tax	0.1	0.3	(0.5)	0.2
Change in foreign currency translation adjustment, net of tax	3.2	0.5	(0.6)	(1.5)
Comprehensive income	7.5	35.3	7.9	100.7
Comprehensive income attributable to non-controlling interest	0.0	0.0	0.0	0.0
Comprehensive income attributable to Myriad Genetics, Inc. shareholders	$ 7.5	$ 35.3	$ 7.9	$ 100.7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 8.9	$ 102.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	35.0	20.0
Non-cash interest expense	0.4
Gain on disposition of assets	(0.2)	(0.4)
Share-based compensation expense	22.7	23.9
Impairment of cost basis investment	2.4
Bad debt expense	27.3	23.5
Loss on extinguishment of debt	1.3
Deferred income taxes	2.0	31.5
Unrecognized tax benefits	0.9	(2.4)
Change in fair value of contingent consideration	2.0
Changes in assets and liabilities:
Prepaid expenses	10.9	(8.7)
Trade accounts receivable	(40.3)	(28.7)
Other receivables	(3.2)	(1.0)
Inventory	(6.5)	(0.2)
Prepaid taxes	3.6	(27.7)
Accounts payable	2.0	(6.9)
Accrued liabilities	(0.6)	2.9
Deferred revenue	1.0
Net cash provided by operating activities	69.6	127.8
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(5.4)	(2.8)
Acquisitions, net of cash acquired	(216.1)
Sale of cost basis investment	2.6
Purchases of marketable investment securities	(74.6)	(131.4)
Proceeds from maturities and sales of marketable investment securities	142.9	86.6
Net cash used in investing activities	(150.6)	(47.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds for common stock issued under share-based compensation plans	1.3	85.9
Net proceeds from revolving credit facility	204.0
Net proceeds from term loan	199.0
Repayment of term loan	(200.0)
Repayment of revolving credit facility	(37.0)
Fees paid for extinguishment of debt	(0.6)
Repurchase and retirement of common stock	(31.6)	(107.9)
Net cash provided by (used in) financing activities	135.1	(22.0)
Effect of foreign exchange rates on cash and cash equivalents	1.2	(1.8)
Net increase in cash and cash equivalents	55.3	56.4
Cash and cash equivalents at beginning of the period	68.5	64.1
Cash and cash equivalents at end of the period	$ 123.8	$ 120.5

Basis of Presentation

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

(1)	BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2016, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016. Operating results for the three and nine months ended March 31, 2017 may not necessarily be indicative of results to be expected for any other interim period or for the full year.

The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company’s management is currently evaluating the impact of adopting ASU 2016-02 on the Company’s consolidated financial statements.

In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, "Revenue from Contracts with Customers." Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. In July 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted for interim and annual periods beginning after the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Acquisitions

9 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Acquisitions

(2)	ACQUISITIONS

Assurex

On August 31, 2016, the Company completed the acquisition of Assurex, pursuant to the Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated August 3, 2016. Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a wholly owned subsidiary of the Company, was merged with and into Assurex, with Assurex continuing as the surviving corporation, and wholly owned subsidiary of Myriad. We acquired Assurex for total consideration of $351.6, net of cash acquired of $5.5, including a cash payment of $216.1, and two potential performance-based milestones totaling $185.0 with a fair value of $130.0. The fair value of the performance-based milestones was determined by using the Monte Carlo method.

Of the cash consideration, $19.1 was deposited into an escrow account to fund (i) any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Assurex at closing, and (ii) any indemnification claims made by Myriad against Assurex within 18 months following closing.

Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their fair values as of the acquisition date including current adjustments as set forth below. We believe the acquisition establishes the foundation for our neuroscience business and leverages our existing preventative care business unit with the addition of a product, GeneSight, which has growth potential. These factors contributed to consideration transferred in excess of the fair value of Assurex’s net tangible and intangible assets acquired, resulting in the Company recording $119.7 in goodwill in connection with the transaction. During the nine months ended March 31, 2017 there were fair value reductions as of the date of the acquisition to intangible assets and equipment totaling $1.7 due to adoption of our capitalization policy which increased goodwill by that amount. During that period there was an adjustment to working capital as of the date of acquisition which required an additional $3.1 cash payment and increased goodwill by that amount. Also during that period there was a $1.4 , $0.8 of which was during the current quarter ended March 31, 2017, decrease in the deferred tax liability due to a change in the blended state tax rate as well as changes in the pre-acquisition deferred tax liabilities which decreased goodwill by the same amount.

Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The preliminary allocation of the consideration transferred is based on a preliminary valuation and is subject to potential adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities and the fair value of equipment, non-controlling interest, as well as tax-related matters, including tax basis of acquired assets and liabilities in a foreign jurisdiction. During the measurement period, the Company may record adjustments to the provisional amounts recognized in the Company’s initial accounting for the acquisition. The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). The preliminary purchase price allocation as of March 31, 2017 is as follows:

	Estimated Fair Value
Current assets	$	18.2
Intangible assets		295.6
Equipment		1.8
Goodwill		119.7
Current liabilities		(18.6	)
Deferred tax liability		(65.1	)
Total fair value purchase price	$	351.6
Less: Contingent consideration		(130.0	)
Less: Cash acquired		(5.5	)
Total cash consideration transferred	$	216.1

Identifiable Intangible Assets

The Company acquired intangible assets that consisted of developed technology which had an estimated fair value of $256.5 and a database with an estimated fair value of $39.1. The fair value of the developed technology was determined using a probability-weighted income approach that discounts expected future cash flows to present value. The fair value of the database was determined using a combination of the lost profits and replacement cost methods. The estimated net cash flows were discounted using a discount rate of 16% which is based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The projected cash flows were based on key assumptions such as: estimates of revenues and operating profits; the time and resources needed to recreate databases and product and commercial development and approval; the life of the commercialized product; and associated risks related to viability and product alternatives. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives of 17 years for the developed technology and 5 years for the database. This amortization is not deductible for income tax purposes. During the year the internally developed software was written off as it was already included in the fair value of the developed technology.

Goodwill

The $119.7 of goodwill represents the excess of consideration transferred over the fair value of assets acquired and liabilities assumed and is attributable to the benefits expected from combining the Company’s research and commercial operations with Assurex’s. This goodwill is not deductible for income tax purposes. Change in goodwill from the date of acquisition is shown below:

	Carrying
	amount
Balance September 30, 2016	$	116.3
Fair value adjustment to equipment and intangibles		1.7
Working capital adjustment		3.1
Change in deferred tax liability		(1.4	)
Ending balance March 31, 2017	$	119.7

Pro Forma Information

The unaudited pro-forma results presented below include the effects of the Assurex acquisition as if it had been consummated as of July 1, 2015, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Assurex. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2015.

	Three months ended				Nine months ended
	March 31,				March 31,
	2017		2016		2017			2016
Revenue	$	196.9	$	207.4	$	582.3		$	610.0
Income from operations		12.9		31.5		25.3			97.1
Net income (loss)		4.2		23.6		(9.1	)		66.6
Net income (loss) per share, basic	$	0.06	$	0.33	$	(0.13	)	$	0.95
Net income (loss) per share, diluted	$	0.06	$	0.32	$	(0.13	)	$	0.91

To complete the purchase transaction, we incurred approximately $5.0 million of acquisition costs, which were recorded as selling, general and administrative expenses. For the three and nine months ended March 31, 2017, Assurex contributed revenue of approximately $23.9 and $53.0, respectively. For the three and nine months ended March 31, 2017 operating expenses related to Assurex were approximately $27.8 and $69.0, respectively.

Sividon

On May 31, 2016 the Company completed the acquisition of Sividon Diagnostics GmbH (“Sividon”), a leading breast cancer prognostic company with cash paid and total cash consideration transferred of $39.0 upfront and the potential for €15.0 ($16.1 converted at the March 31, 2017 period end exchange rate) in additional performance-based milestones.

Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their fair values at the acquisition date as set forth below. We believe the acquisition brings us the best-in-class breast cancer prognostic test and strengthens our market leading oncology portfolio of high value personalized medicine products which can be expanded internationally as well as brought to the US market. These factors contributed to consideration transferred in excess of the fair value of Sividon’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. The goodwill related to the purchase is not tax deductible.

Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The preliminary allocation of the consideration transferred is based on a preliminary valuation and is subject to potential adjustments. Balances subject to adjustment primarily include tax-related matters, including tax basis of acquired assets and liabilities in the foreign jurisdiction. During the measurement period, the Company may record adjustments to the provisional amounts recognized in the Company’s initial accounting for the acquisition. The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). Based upon updated fair value calculations as of the purchase date there was a decrease in contingent consideration of $0.4 and intangibles of $0.4 which increased goodwill by $0.8 during the nine months ended March 31, 2017.

	Estimated Fair
	Value
Current assets	$	2.7
Intangible assets		45.8
Equipment		0.3
Goodwill		18.5
Current liabilities		(15.4	)
Total fair value purchase price	$	51.9
Less: Contingent consideration		(10.9	)
Less: Cash acquired		(2.0	)
Total cash consideration transferred	$	39.0

The acquisition of Sividon has been deemed insignificant in relation to the consolidated financial statements. As such, pro forma financial information is not provided.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Marketable Investment Securities

9 Months Ended

Mar. 31, 2017

Investments Debt And Equity Securities [Abstract]

Marketable Investment Securities

(3)	MARKETABLE INVESTMENT SECURITIES

The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2017 and June 30, 2016 were as follows:

			Gross		Gross
			unrealized		unrealized
	Amortized		holding		holding			Estimated
	cost		gains		losses			fair value
At March 31, 2017:
Cash and cash equivalents:
Cash	$	106.6	$	—	$	—		$	106.6
Cash equivalents		17.2		—		—		$	17.2
Total cash and cash equivalents		123.8		—		—			123.8
Available-for-sale:
Corporate bonds and notes		41.5		—		(0.1	)		41.4
Municipal bonds		43.5		—		—			43.5
Federal agency issues		11.6		—		—			11.6
US government securities		5.2		—		—			5.2
Total	$	225.6	$	—	$	(0.1	)	$	225.5

			Gross		Gross
			unrealized		unrealized
	Amortized		holding		holding		Estimated
	cost		gains		losses		fair value
At June 30, 2016:
Cash and cash equivalents:
Cash	$	66.1	$	—	$	—	$	66.1
Cash equivalents		2.4		—		—		2.4
Total cash and cash equivalents		68.5		—		—		68.5
Available-for-sale:
Corporate bonds and notes		50.8		0.2		—		51.0
Municipal bonds		85.4		0.2		—		85.6
Federal agency issues		25.5		—		—		25.5
US government securities		8.2		0.1		—		8.3
Total	$	238.4	$	0.5	$	—	$	238.9

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at March 31, 2017:

	Amortized		Estimated
	cost		fair value
Cash	$	106.6	$	106.6
Cash equivalents		17.2		17.2
Available-for-sale:
Due within one year		48.3		48.3
Due after one year through five years		52.0		51.9
Due after five years		1.5		1.5
Total	$	225.6	$	225.5

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Property, Plant and Equipment, Net

9 Months Ended

Mar. 31, 2017

Property Plant And Equipment [Abstract]

Property, Plant and Equipment, Net

(4)	PROPERTY, PLANT AND EQUIPMENT, NET

	March 31,			June 30,
	2017			2016
Land	$	2.2		$	2.3
Buildings and improvements		16.3			17.3
Leasehold improvements		22.0			18.7
Equipment		105.8			103.4
		146.3			141.7
Less accumulated depreciation		(93.3	)		(83.4	)
Property, plant and equipment, net	$	53.0		$	58.3

	Three months ended				Nine months ended
	March 31,				March 31,
	2017		2016		2017		2016
Depreciation expense	$	3.7	$	3.5	$	11.0	$	10.6

Goodwill and Intangible Assets

9 Months Ended

Mar. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

(5)	GOODWILL AND INTANGIBLE ASSETS

Goodwill

The Company has recorded goodwill of $315.0 from the acquisitions of Assurex that was completed on August 31, 2016, Sividon that was completed on May 31, 2016, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $249.9 relates to the Company’s diagnostic segment and $65.1 relates to the other segment. The following summarizes changes to the goodwill balance for the nine months ended March 31, 2017:

	Carrying amount
Beginning balance July 1, 2016	$	195.3
Acquisitions (see note 2)		119.7
Adjustments to acquisitions (see note 2)		0.8
Translation adjustments		(0.8	)
Ending balance March 31, 2017	$	315.0

Intangible Assets

Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:

	Gross
	Carrying		Accumulated
	Amount		Amortization			Net
At March 31, 2017:
Purchased licenses and technologies	$	523.9	$	(52.0	)	$	471.9
Customer relationships		4.7		(2.7	)		2.0
Trademarks		3.0		(0.8	)		2.2
Total amortized intangible assets		531.6		(55.5	)		476.1
In-process research and development		22.0		—			22.0
Total unamortized intangible assets		22.0		—			22.0
Total intangible assets	$	553.6	$	(55.5	)	$	498.1

	Gross
	Carrying		Accumulated
	Amount		Amortization			Net
At June 30, 2016:
Purchased licenses and technologies	$	228.7	$	(28.5	)	$	200.2
Customer relationships		4.7		(2.4	)		2.3
Trademarks		3.0		(0.6	)		2.4
Total amortized intangible assets		236.4		(31.5	)		204.9
In-process research and development		22.6		—			22.6
Total unamortized intangible assets		22.6		—			22.6
Total intangible assets	$	259.0	$	(31.5	)	$	227.5

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

	Three months ended				Nine months ended
	March 31,				March 31,
	2017		2016		2017		2016
Amortization of intangible assets	$	9.2	$	3.1	$	24.0	$	9.4

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Cost Basis Investment

9 Months Ended

Mar. 31, 2017

Investments All Other Investments [Abstract]

Cost Basis Investment

(6)	COST BASIS INVESTMENT

During the quarter ended March 31, 2017, the Company sold its investment in RainDance Technologies, Inc., which had been recorded under the cost method as an “Other Asset” on the Company’s condensed consolidated balance sheet. Initial cost method fair value of the investment was $5.0. During the quarter ended December 31, 2016 we recognized a $2.4 impairment on this investment based on indications suggesting that the fair value of this investment was impaired. During the quarter ended March 31, 2017 the remaining investment was sold for $2.6.

Accrued Liabilities

9 Months Ended

Mar. 31, 2017

Payables And Accruals [Abstract]

Accrued Liabilities

(7)	ACCRUED LIABILITIES

	March 31,			June 30,
	2017			2016
Employee compensation and benefits	$	49.3		$	37.3
Accrued taxes payable		3.0			2.8
Other		11.7	<